This study showed that the ECMO group exhibited a significantly lower mortality rate compared with the MV alone group at 90, 30 and 60 days for severe ARDS patients.
Here, we report our single-center experience with bivalirudin anticoagulation in "on-pump" and "off-pump" cardiac surgery in a large number of patients with and without heparin antibodies.
